Phytovid19: a compilation of phytochemicals research in coronavirus

Anasuya Bhargav1,2 · Pratibha Chaurasia1,2 · Rohit Kumar1,2 · Srinivasan Ramachandran1,2

Received: 18 April 2022 / Accepted: 9 August 2022 / Published online: 25 August 2022
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022

Abstract
The COVID-19 pandemic has immensely impacted global health causing colossal damage. The recent outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has increased the quest to explore phytochemicals as treatment options. We summarize phytochemicals with activity against various coronaviruses including SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV). We compiled 705 phytochemical compounds through text mining of 893 PubMed articles. The physicochemical properties including molecular weight, lipophilicity, and the number of hydrogen bond donors and acceptors were determined from the structures of these compounds. A structure-based evaluation of these properties with respect to drug likeness showed that most compounds have a positive score of drug likeness. QSAR analysis showed that 5 descriptors, namely polar surface area, relative polar surface area, number of hydrogen bond donors, solubility, and lipophilicity, are significantly related to IC50. We envisage that these phytochemicals could be further explored for developing new potential therapeutic molecules for COVID-19.

Keywords COVID-19 · Phytochemicals · Text mining · Cheminformatics · Physicochemical properties

Introduction
The COVID-19 pandemic caused by novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has caused colossal damage worldwide [1]. Coronaviruses consist of a large diverse family of viruses, namely, Alpha-, Beta-, Gamma-, and Delta coronaviruses. The SARS-CoV-2 belongs to the beta subfamily, which also includes the SARS-CoV and bat CoV ZXC21. CoV ZXC21 and CoV ZC45 are closest to SARS-CoV-2. SARS-CoV-2 shares 76.04% amino acid sequence identity in the Spike (S)-protein sequence with that of SARS-CoV, 80.32% with bat CoV ZXC21 Spike protein, and 81.00% identity to the sequences of Spike proteins of bat-derived SARS-like coronaviruses bat-SL-CoVZC45 and 35.10% identity to the sequence of the Spike protein of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) [2]. SARS-CoV-2 is a single-stranded RNA virus with at least ten open reading frames (ORFs) [3]. The first set of ORFs (ORF1a/b) code for polyproteins and the remaining encode for four main structural proteins of the virus. These structural proteins are, namely, spike (S), envelope (E), nucleocapsid (N), and membrane (M) proteins [4, 5]. The Spike glycoprotein mediates the invasion of coronaviruses into human cells by interacting with the ACE2 receptors [6]. The Spike glycoprotein has a large ectodomain, a single-pass transmembrane anchor, and a short C-terminal tail. The ectodomain contains a receptor-binding unit S1 that binds to cell surface receptors. The S2 unit of the ectodomain fuses with the host cell and viral membranes thereby enabling the entry of viral genomes into host cells [7].

SARS-CoV-2 causes infections mainly in the respiratory tract and lungs [8]. Virus excretions from gastrointestinal tracts have also been observed. The ongoing COVID-19 pandemic has caused over 575,887,049 infections and over 6,398,412 deaths (data as of 02 Aug 2022, 9:34 pm CEST) worldwide and the numbers are still rising [9]. Several different strains have emerged in different countries since the beginning of the pandemic causing a huge disease burden on...
global health and the economy. Despite significant efforts, there are no specific anti-COVID-19 therapies available [10]. Patients with associated comorbidities, namely, chronic respiratory disease, cardiovascular disease, cancer, or diabetes, tend to be susceptible to infection. In one study, Guan et al. (2020) reported that 25.1% of Chinese patients have at least one associated comorbidity, and 8.2% of patients had two or more comorbidities. The major comorbidities were hypertension (16.9%), diabetes (8.2%), cardiovascular diseases (3.7%), and chronic kidney diseases (1.3%) [11]. Meta-analysis of various comorbidities suggested that leukemia, psoriasis, and non-alcoholic fatty liver (NFLD) patients are at higher risk [12]. Therefore, there is a pressing demand for effective therapeutic solutions for the treatment of COVID-19 [13].

Human civilization has looked high and low into nature for healing strategies ever since ancient times [14]. Several time-honoured drugs were prepared from plant parts and are in use even today. Due to their potentially high therapeutic qualities and acceptance by patients with diverse health issues, herbal medications play a significant role in treating a variety of disorders. The use of a plant’s complete body, a specific isolated phytoconstituent, or a portion of the plant are all part of the practice of herbal medicine. The discovery of herbal medicines from various natural resources rekindled interest in the scientific era’s hunt for novel pharmaceuticals [15]. Examples of drugs include morphine, antibiotics such as penicillin, erythromycin, cardiac stimulant digoxin, salicylic acid (aspirin), reserpine (antipsychotic and anti-hypertensive), quinine (antimalarial), and lovastatin (lipid-reducing) [16–18]. Many therapeutics under development for cancer are using natural products. Paclitaxel is a widely known anticancer compound from natural plant sources. Several anticancer therapeutics have been developed through combinatorial chemistry from the original natural source [19]. The use of natural plant compounds over many years has been noted to be well tolerated, more affordable, and accessible. Not surprisingly, the discovery of therapeutics against SARS progressed rapidly and significantly by searching the natural plant source compounds. Various phytochemicals have been reported to have prophylactic activity against MERS and SARS coronaviruses. For example, leptodactylone extracted from Boenninghausenia sessilicarpa was reported to have 60% of anti-SARS-CoV activity at 100 µg/ml concentration [20].

Recently, some phytochemicals were studied in COVID patients as complementary treatment options, for example, ginger, traditional Chinese medicine Bufeil Huoxue capsules etc. [21, 22]. The traditional Chinese herbal medicine therapy, recommended by Chinese herbalists, includes a combination of herbs, based on the distinction of the patient’s syndrome. Traditional Chinese herbal medicine therapies were said to have effectively prevented and cured SARS during the outbreaks. It was used extensively for the treatment of SARS in 2002 and was administered to 58.3% of confirmed patients [23]. For example, the Traditional Chinese Medicine (TCM) Ma xing shi gan decoction (MXSG) is made up of four herbs namely, Ephedra sinensis, Semen armeniacae amarum, Glycyrrhiza, and Gypsum fibrosum. The major therapeutic role of this herbal medicine is to treat asthma, lung heat, and cough. This TCM can be used for early coronavirus infections [24].

In this paper, we examine how different types of herbs responded to the SARS virus pandemic during its early phases and we evaluate major results on how early warning systems created during earlier epidemics responded to limit the virus. We have used themes of coronavirus, and herbs in data mining of scientific literature records from the NCBI PubMed database [25]. The CRAN package pubmed.mineR [26] was used for text mining. The records were individually examined, and the results are contrasted with records covering all of the Covid-19 study themes. From the positively curated literature dataset, herbal compounds with anti-coronavirus activity were shortlisted to facilitate therapeutic development against these highly health and economy-disrupting diseases. A compound dataset was prepared from text mining. The quantitative descriptors of selected compounds such as molecular weight, polar surface area, number of hydrogen bond donors and acceptors, lipophilicity, drug likeness along with reported activity, i.e., 50% inhibitory concentration (IC50) were examined. Following that, a quantitative structure–activity relationship (QSAR) was drawn out using statistical techniques between activity and physiological descriptors that were significantly related to the activity.

**Methodology**

**Text mining** PubMed (https://pubmed.ncbi.nlm.nih.gov/) database [25] was searched using specific keywords, “COVID-19 OR SARS-CoV-2 OR Severe acute respiratory syndrome coronavirus-2 OR Coronavirus) AND Herbal”. Abstracts were retrieved on 16.02.2022. All text mining work was carried out using the R package pubmed.mineR version 1.0.19 [26]. The abstract set was first to read using readabsnew() function. To extract species and chemical entities, the pubtator_function was used. The extracted data were manually examined to include those mentioning phytochemicals or natural compounds and plant species.

**Inclusion and exclusion criteria** Specific criteria chosen for text mining were as follows:

- **In silico** studies were excluded.
- Only articles with accessible full text were included.
• *In vivo, in vitro*, and random clinical trials were included.
• Reviews were included.
• Phytochemicals with reported activity against SARS and MERS were included.

Through manual curation, studies focussing on SARS and MERS viruses were shortlisted. We examined for phytochemicals and herbal compounds and their reported activities, namely, inhibitory concentration (IC50) if any. For example, the review article by Silveira et al., 2020 described different herbal medicines as adjuvants for Covid-19 [27]. This article was categorized as “positive” in manual curation and names of different herbal medicines extracted from this review were included in the final compound dataset. On the other hand, Gani et al., 2021 carried out a computational screening of biologically active metabolites from Indonesian plants [28]. This study was classified as “negative” as it was performed in silico.

**Structure retrieval** The PubChem database (https://pubchem.ncbi.nlm.nih.gov/) was referred for retrieval of chemical structures. The 3D (most preferably) or 2D (when 3D was unavailable) structures were downloaded [29]. The compound dataset was prepared by assigning a unique ID to each compound. Redundant compounds from multiple PMIDs were removed.

**Analysis of physicochemical properties** Various physicochemical properties were analyzed using DataWarrior software [30]. DataWarrior is open-source software for structure-based data analysis and visualization. The structures of herbal compounds extracted through text-mining were first loaded into DataWarrior. The physicochemical properties calculated from structures include Lipinski’s properties, solubility, polar surface area, and drug likeness. Further, the distribution of these properties across the compounds of the dataset was plotted.

**Quantitative structure–activity relationship** Quantitative structure–activity relationship (QSAR) is used for quantifying the effect of physicochemical properties on the biological activity of compounds [31]. Different descriptors may contribute to and affect the activity of compounds, and hence the highly correlated features among different descriptors were identified. This analysis was performed using *cor* function in R. The descriptors were, namely, molecular weight (MW), lipophilicity (cLogP), solubility (cLogS), number of hydrogen bond acceptors (HA) and donors (HD), total surface area (TSA), polar surface area (PSA), drug likeness (DL), relative polar surface area (RPSA), molecular shape index (SI), molecular flexibility (MF), molecular complexity (MC), and reported IC50. Linear regression-based statistical modelling was used with IC50 as the dependent variable. The compounds dataset used here is a subset of literature retrieved compounds with reported IC50 values. These compounds have different targets such as SARS-CoV S protein-ACE2 interaction, 3CLpro, PLpro, helicase, viroporin 3a, ACE receptor, and compounds targeting endocytic machinery [32] and reported with a role in increasing intracellular Zn2+ concentration [33]. Further, to fit the linear models, *lm* function in R was used. Only the significant descriptors with a p-value ≤ 0.05 were considered. The estimated regression equation was derived as $Y = mX + c$, where $Y$ is IC50 and $X$ is the selected descriptor.

**Result and discussion**

**Text mining** From the PubMed database, 893 abstracts were retrieved with the given keywords. This abstract set was further used as a primary dataset for text mining and data collection. This dataset contains original research articles, reviews, meta-analysis studies, trials, comment articles, case reports, multicentre studies, observational studies, and letters to editors. Using the *pubtator_function* of pubmed.mineR package, 222 abstracts were screened from the whole abstract set. This selection was based on the exclusion and inclusion criteria mentioned in the methodology section. Word atomization shows that the frequency of specific terms, namely, “medicine,” “Chinese,” “treatment,” “herbal,” and “traditional” are prominent in these abstracts. This highlights the importance of natural product-based treatments regarding Covid-19. A graphical representation of the same is shown as a word cloud in Fig. 1a.

**Phytochemicals for Covid-19** Phytochemicals and natural products have been abundantly explored for Covid-19. Yearwise inspection of the 893 retrieved abstracts shows that there is a drastic increase in herbal product-related studies after the COVID-19 pandemic began. The abstract set contains only 5 abstracts from the year 2011, which increased to 393 in 2020 and 494 in 2021 (Fig. 1b). Our extensive literature review collects phytochemicals belonging to classes such as phenolic acids, terpenes, and coumarins.

- Phenolic acids: Phenolic acids are secondary plant metabolites, majorly present in cereals and berries [34, 35]. These are derivatives of cinnamic and benzoic acids [36]. Kim et al. 2014 identified polyphenolic compounds from *Pso ralea corylifolia* seeds having inhibitory activity against papain-like protease (PLpro) of SARS-CoV [37]. The herbal medicine *Ocimum gratissimum* contains phenolic compounds and their derivatives like quercetin, luteolin, caffeic acid [38, 39] and can be used for relieving early COVID-19 symptoms [27]. Other examples of antiviral phenolic acids include caffeic acid, gallic acid, and caffeoylquinic.
acids. Chlorogenic acid is a caffeic acid derivative extracted from *Echinacea purpurea* with IC50 0.1 μM against ACE inhibitory activity [40]. Xing et al. 2014 reported that gallic acid isolated from *Tamarix hohenackeri* Bunge had ACE-inhibitory activity with 20 mg/ml of EC50 [41].

Flavonoids are classes of polyphenolic compounds, abundant in fruits and vegetables. They possess anti-inflammatory, anti-oxidative, anti-carcinogenic, and anti-mutagenic properties [42]. Several reports have suggested the antiviral activity of different flavonoids against viruses including respiratory syncytial virus, human immunodeficiency virus (HIV), and herpes simplex virus (HSV). For example, the flavonoid baicalin inhibits infection and replication of HIV-1 [43, 44]. Numerous studies have reported the activity of flavonoid compounds against respiratory viruses belonging to the SARS family. The roots and leaves of *Althaea officinalis* L contain different flavonoids namely, Isoscutellarein, hynolaetin, kaempferol, and luteolin [45]. The extracts from this plant can suppress cough and are therefore reported as potential use in COVID-19 [27]. Yi et al. 2004 had reported that Luteolin and quercetin can inhibit SARS-CoV spike protein (S) through interaction with ACE2 receptors [46].

Among the flavonoids, chalcones are aromatic ketones and enones [47]. Chalcones like broussochalcone A and B were reported to have activity against coronavirus-chymotrypsin-like protease (3CLpro) [48]. Park et al. 2016 studied alkylated chalcones from *Angelica keiske*. These include various Xanthoangelol compounds with IC50 ranging between 1.2 and 13 μM against 3CLpro and PLpro of SARS-CoV [49]. Prenylated flavonoids like Tomentin (A-E) extracted from the fruits of *Paulownia tomentosa* were reported as competitive inhibitors of SARS-CoV papain-like protease (PLpro) with IC50 ≤ 12.5μM [50]. Other categories of flavonoids like glycosides were mentioned to have an antiviral activity such as Juglanine inhibits ion channel activity of SARS-CoV 3a protein with IC50 of 2.3 μM [51]. Further, Carlino-
As Coumarin derivatives were earlier studied in respiratory diseases, therefore such compounds can be of great importance as an anti-Covid-19 agent. Several herbal medicines for respiratory diseases contain coumarins including roots and leaves of *Althaea officinalis*, roots of *Glycyrrhiza glabra* and *Justicia pectoralis* [27]. In a recent study, extracts from *Angelica decursiva* were reported to have anti-ACE activity with IC50 of 20 μM [64]. Coumarins including Decursidin extracted from *Angelica decursiva* plant showed IC50 ranging between 4.68 and 20.04 μM [64].

The recent surge in COVID-19 infection has increased the investigation of traditional medicines as part of modern medicine. An overwhelming 705 compounds (Supplementary Table S1) were compiled through this literature survey. These provide a better understanding of phytochemicals that can be explored further against SARS-CoV-2. As evident from the literature survey, many randomized control trials have been conducted to study the effect of herbal formulations on alleviating COVID-19 symptoms [65]. A few phytochemicals are also being evaluated in clinical trials as a potential therapy for COVID-19 [65] as per data on ClinicalTrials.gov. We have enlisted 11 completed (Supplementary Table S2) clinical trials using herbal products as interventions for the treatment of COVID-19. This list includes clinical trials using natural products such as Colchicine, curcumin, Plitidepsin, Essential Oil, *Nigella Sativa* oil, Xagrotin, and Vitamin C. The consolidated list is shown in Supplementary Table S2.

**Compounds dataset** The structure of 705 literature retrieved compounds with possible antiviral activity against different coronaviruses was extracted from PubChem and a compound dataset was prepared. Evaluation of functional groups revealed that these compounds contain amine nitrogen including imides and sulfonamides, amines, alkyl-amines, aromatic and basic nitrogen atoms, and acidic oxygen atom count. Literature studies confirm the antiviral property of these compounds with these functional groups [66–70].

---

**Fig. 2** Distribution of physicochemical properties. a Molecular weight, b cLogP, c number of hydrogen bond donors, and d number of hydrogen bond acceptors, with respect to drug likeness.
Further, physicochemical properties and drug likeness of each compound were also calculated using DataWarrior. The drug likeness is a quantitative measure of how various physicochemical properties can affect the drug ability of any compound. The higher the score, the more the drug likeness of any compound. The distribution of molecular weight, lipophilicity, and the number of hydrogen bond donors and acceptors with respect to drug likeness is shown in Fig. 2. It is apparent that most compounds lie in the positive range of drug likeness score.

**QSAR analysis** For QSAR analysis, 109 compounds with reported IC50 were selected. As it can be observed from the correlation plot in Fig. 3a, 6 descriptors, cLogS, HD, HA, PSA, RPSA, and DL, are positively correlated with IC50 whereas cLogP, SI, and MF are negatively correlated with IC50. Further, linear regression analysis was carried out using descriptors correlated with IC50. Of these selected descriptors, 5 were found to be significant (p < 0.05) namely cLogP, cLogS, PSA, RPSA, and HA (Supplementary Table S3) and the other 4 descriptors such as DL, MF, MC, and HD were not found to be significant. After model fitting, 5 different lines of the equation were derived (Table 1). HA, PSA, RPSA, and cLogS followed a positive linear relationship with IC50, whereas cLogP followed a negative linear relationship (Fig. 3b).

### Table 1: Quantitative structure activity relationship of IC50 with descriptors

| Descriptors                          | p-value  | Linear equation          |
|--------------------------------------|----------|--------------------------|
| Lipophilicity (cLogP)                | 0.00164  | IC50 = 65.304 - 7.152*cLogP |
| Solubility (cLogS)                   | 0.001949 | IC50 = 83.964 + 10.826*cLogS |
| Number of hydrogen bond acceptor (HA)| 0.03764  | IC50 = 28.406 + 1.790*HA |
| Topological polar surface area (PSA) | 0.04359  | IC50 = 28.825 + 0.101*PSA |
| Relative polar surface area (R_PSA)  | 0.000554 | IC50 = 154.06*R_PSA - 3.254 |


**Conclusion**

The current COVID-19 pandemic has impacted global health severely. Along with modern medicine, traditional remedies are rapidly emerging as potent therapies. In this compilation, we have carried out extensive text mining to obtain insights into various phytochemicals with potent activity against coronaviruses. Comprehensively, 893 abstracts were retrieved from the PubMed database for text mining using specific query terms and a dataset of 705 compounds was prepared. This dataset contains phytochemicals of classes including phenolic acids, flavonoids, terpenes, and coumarins. QSAR study using linear regression predicted that physicochemical properties like PSA, HA, and cLogS follow a positive linear relationship with minimum inhibitory concentration (IC50) whereas, cLogP follows a negative relation. We envision that this comprehensive review will be helpful for obtaining insights into phytochemicals with activity against coronaviruses. Also, a quantitative understanding of various physicochemical properties of the phytochemicals can be informative for future drug development.

We confirm that the manuscript is original and has not been published before.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1007/s11224-022-02035-6.

**Author contribution**

The study was designed by Anasuya Bhargav, Pratibha Chaurasia, and Srinivasan Ramachandran, data collection was performed by Anasuya Bhargav, Pratibha Chaurasia, and Rohit Kumar, and the manuscript was written by Anasuya Bhargav, Pratibha Chaurasia, Rohit Kumar, and Srinivasan Ramachandran. The manuscript has been read and approved by all authors.

**Funding**

Srinivasan Ramachandran’s work is supported in part by a grant from ICMR (No. BIC/5(09)/Indo-Russian/2016). Anasuya Bhargav, Pratibha Chaurasia, and Rohit Kumar acknowledge UGC for fellowship.

**Data availability**

The dataset analyzed during the current study is available as supplementary files.

**Code availability**

Not applicable.

**Declarations**

**Competing interests**

The authors declare no competing interests.

**References**

1. Coronavirus disease (COVID-19) – World Health Organization. [https://www.who.int/emergencies/diseases/novel-coronavirus-2019](https://www.who.int/emergencies/diseases/novel-coronavirus-2019). Accessed 30 Mar 2022
2. Coutard B, Valle C, de Lamberlere X, Canard B, Seidah NG, Decroly E (2020) The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Res 176:104742. [https://doi.org/10.1016/j.antiviral.2020.104742](https://doi.org/10.1016/j.antiviral.2020.104742)
3. Choudhary J et al (2021) Insights of severe acute respiratory syndrome coronavirus (SARS-CoV-2) pandemic: a current review. Biol Proced Online 23(1):5. [https://doi.org/10.1186/s12575-020-00141-5](https://doi.org/10.1186/s12575-020-00141-5)
4. Li X, Geng M, Peng Y, Meng L, Lu S (2020) Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal 10(2):102–108. [https://doi.org/10.1016/j.jpha.2020.03.001](https://doi.org/10.1016/j.jpha.2020.03.001)
5. Rani J, Bhargav A, Khan FI, Ramachandran S, Lai D, Bajpai U (2021) In silico prediction of natural compounds as potential multi-target inhibitors of structural proteins of SARS-Cov-2. J Biomol Struct Dynnp 1–17. [https://doi.org/10.1080/07391102.2021.1968497](https://doi.org/10.1080/07391102.2021.1968497)
6. Jin DY, Zheng BJ (2009) “Roles of spike protein in the pathogenesis of SARS coronavirus”, Hong Kong Med J. Xianggang Yi Xue Za Zhi 15(Suppl 2):37–40
7. Chen Y, Guo Y, Pan Y, Zhao ZJ (2020) Structure analysis of the receptor binding of 2019-nCoV. Biochem Biophys Res Comm pp. S0006–291X(20)30339–9. [https://doi.org/10.1016/j.bbrc.2020.02.071](https://doi.org/10.1016/j.bbrc.2020.02.071)
8. Pal M, Berhanu G, Desalegn C, Kandi V (2020) Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): an update. Cureus 12(3):e7423. [https://doi.org/10.7759/cureus.7423](https://doi.org/10.7759/cureus.7423)
9. WHO Coronavirus (COVID-19) Dashboard. [https://covid19.who.int.](https://covid19.who.int.) Accessed 30 Mar 2022
10. Mesri M et al (2021) The effects of combination of Zingiber officinale and Echinacea on alleviation of clinical symptoms and hospitalization rate of suspected COVID-19 outpatients: a randomized controlled trial. J Complement Integr Med 18(4):775–781. [https://doi.org/10.1515/jcim-2020-0283](https://doi.org/10.1515/jcim-2020-0283)
11. Guan W-J et al (2020) Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J 55(5):2000547. [https://doi.org/10.1183/13993003.00547-2020](https://doi.org/10.1183/13993003.00547-2020)
12. Singh MK, Mobeen A, Chandra A, Joshi S, Ramachandran S (2021) A meta-analysis of comorbidities in COVID-19: which diseases increase the susceptibility of SARS-CoV-2 infection? Comput Biol Med 130:104219. [https://doi.org/10.1016/j.compbiomed.2021.104219](https://doi.org/10.1016/j.compbiomed.2021.104219)
13. Soleymani S et al (2022) COVID-19: general strategies for herbal therapies. J Evid-Based Integr Med 27:2515690X211053641. [https://doi.org/10.1177/2515690X211053641](https://doi.org/10.1177/2515690X211053641)
14. Petrovskova BB (2012) Historical review of medicinal plants’ usage. Pharmacogn Rev 6(11):1–5. [https://doi.org/10.4103/0973-7847.95849](https://doi.org/10.4103/0973-7847.95849)
15. Barkat MA, Goyal A, Barkat HA, Salauddin M, Potoo FH, Anwer ET (2021) Herbal Medicine: clinical perspective and regulatory status. Comb Chem High Throughput Screen 24(10):1573–1582. [https://doi.org/10.2174/1386207323999201110192942](https://doi.org/10.2174/1386207323999201110192942)
16. Rishton GM (2008) Natural products as a robust source of new drugs and drug leads: past successes and present day issues. Am J Cardiol 101(10A):43D–49D. [https://doi.org/10.1016/j.amjcard.2008.02.007](https://doi.org/10.1016/j.amjcard.2008.02.007)
17. Schmidt B, Ribnicky DM, Poulev A, Logendra S, Cefalu WT, Raskin L (2008) A natural history of botanical therapeutics. Metabolism 57(7 Suppl 1):S3-9. [https://doi.org/10.1016/j.metabol.2008.03.001](https://doi.org/10.1016/j.metabol.2008.03.001)
18. Li JW-H, Vedera JC (2009) Drug discovery and natural products: end of an era or an endless frontier? Science 325(5937):161–165. [https://doi.org/10.1126/science.1168243](https://doi.org/10.1126/science.1168243)
19. Benzie IFF, Wachtel-Galor S Eds (2011) Herbal medicine: biomedical and clinical aspects, 2nd ed. Boca Raton (FL): CRC Press/Taylor & Francis. [Online]. Available: [http://www.ncbi.nlm.nih.gov/books/NBK92771/](http://www.ncbi.nlm.nih.gov/books/NBK92771/). Accessed 30 Mar 2022
20. Yang Q-Y, Tian X-Y, Fang W-S (2007) Bioactive coumarins from Boehninghausenia sessilicarpa. J Asian Nat Prod Res 9(1):59–65. [https://doi.org/10.1080/10286020500382397](https://doi.org/10.1080/10286020500382397)
21. Safa O et al (2020) Effects of Ginger on clinical manifestations and paraclinical features of patients with severe acute respiratory syndrome due to COVID-19: a structured summary of a study protocol for a randomized controlled trial. Trials 21(1):841. https://doi.org/10.1186/s13063-020-04765-6

22. Chen Y et al (2022) Efficacy and safety of Bufei Huoxue capsules in the management of convalescent patients with COVID-19 infection: a multicentre, double-blind, and randomised controlled trial. J Ethnopharmacol 284:114830. https://doi.org/10.1016/j.jep.2021.114830

23. Li Y et al (2020) Traditional Chinese herbal medicine for treating novel coronavirus (COVID-19) pneumonia: protocol for a systematic review and meta-analysis. Syst Rev 9(1):75. https://doi.org/10.1186/s13643-020-01344-4

24. Lee DYW, Li QY, Liu J, Effert T (2021) Traditional Chinese herbal medicine at the forefront battle against COVID-19: clinical experience and scientific basis. Phytomedicine Int J Phytother Phytopharm 80:153337. https://doi.org/10.1016/j.phymed.2020.153337

25. PubMed (2022) PubMed. https://pubmed.ncbi.nlm.nih.gov/. Accessed 30 Mar 2022

26. Rani J, Shah ABR, Ramachandran S (2015) pubmed minedR: an R package with text-mining algorithms to analyse PubMed abstracts. J Biosci 40(4):671–682. https://doi.org/10.1007/s12038-015-9552-2

27. Silveira D et al (2020) COVID-19: is there evidence for the use of herbal medicines as adjuvant symptomatic therapy? Front Pharmacol 11:581840. https://doi.org/10.3389/fphar.2020.581840

28. Gani MA, Nurhan AD, Maulana S, Sissowdiharjo S, Shinta DW, Khotib J (2021) Structure-based virtual screening of bioactive compounds from Indonesian medical plants against severe acute respiratory syndrome coronavirus-2. J Adv Pharm Technol Res 12(2):120–126. https://doi.org/10.4103/japtr.JAPTR_88_21

29. Kim S et al (2021) PubChem in 2021: new data content and improved web interfaces. Nucleic Acids Res 49(D1):D1388–D1395. https://doi.org/10.1093/nar/gkaa971

30. Sander T, Freyss J, von Korff M, Rufener C (2015) DataWarrior: an open-source program for chemistry aware data visualization and analysis. J Chem Inf Model 55(2):460–473. https://doi.org/10.1021/ci5005588

31. Kwon S, Bae H, Jo J, Yoon S (2019) Comprehensive ensemble in QSAR prediction for drug discovery. BMC Bioinformatics 20(1):521. https://doi.org/10.1186/s12859-019-3135-4

32. SARS coronavirus entry into host cells through a novel clathrin- and caveolea-independent endocytic pathway I Cell Research. https://www.nature.com/articles/cr200815. Accessed 30 Mar 2022

33. Zn2+ inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture. https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1001176. Accessed 30 Mar 2022

34. Robbins RJ (2003) Phenolic acids in foods: an overview of analytical methodology. J Agric Food Chem 51(10):2866–2887. https://doi.org/10.1021/jf026182t

35. Padmanabhan P, Correa-Betanzo J, Paliyath G (2016) Berries and related fruits; in Encyclopedia of Food and Health, Caballero B, Finglas PM, Toldra F Eds. Oxford: Academic Press. pp. 364–371.

36. Menon R, Gonzalez T, Ferruzzi M, Jackson E, Winderl D, Watson J (2016) Chapter one - oats—from farm to fork; in Advances in Food and Nutrition Research, vol. 77, Henry J Ed. Academic Press pp. 1–55. https://doi.org/10.1016/bs.afnr.2015.12.001

37. Kim DW et al (2014) Phenolic phytochemicals displaying SARS-CoV papain-like protease inhibition from the seeds of Psoralea corylifolia. J Enzyme Inhib Med Chem 29(1):59–63. https://doi.org/10.3109/14756366.2012.753591

38. SM et al (2016) Ocimum sanctum: a review on the pharmacological properties. Int J Basic Clin Pharmacol pp. 558–565. https://doi.org/10.18203/2319-2003.jbcp20161491

39. Prabhu KS, Lobo R, Shirwaikar AA, Shirwaikar A (2009) Ocimum gratissimum: a review of its chemical, pharmacological and ethnomedicinal properties. Open Complement Med J 1(1). [Online]. Available: https://benthamopen.com/ABSTRACT/TOALTMEDJ-1-1. Accessed 30 Mar 2022

40. Chiuo S-Y, Sung J-M, Huang P-W, Lin S-D (2017) Antioxidant, Antidiabetic, and antihypertensive properties of Echinacea purpurea flower extract and caffeic acid derivatives using in vitro models. J Med Food 20(2):171–179. https://doi.org/10.1089/jmf.2016.3790

41. Xing Y et al (2014) ACE and platelet aggregation inhibitors from Tamarix hohenackeri Bunge (host plant of Herba Cistanches) growing in Xinjiang. Pharmacogn Mag 10(38):111–117. https://doi.org/10.4101/jipm.2016.1186

42. Panche AN, Diwan AD, Chandra SR (2016) Flavonoids: an overview. J Nutr Sci 5:e47. https://doi.org/10.1017/jns.2016.41

43. Li BQ, Fu T, Dongyan Y, Mikovits JA, Ruscetti FW, Wang JM (2000) Flavonoid baicalin inhibits HIV-1 infection at the level of viral entry. Biochem Biophys Res Commun 276(2):534–538. https://doi.org/10.1016/j.bbrc.2000.3485

44. Li BQ, Fu T, Yan YD, Baylor NW, Ruscetti FW, Kung HF (1993) Inhibition of HIV infection by baicalin—a flavonoid compound purified from Chinese herbal medicine. Cell Mol Biol Res 39(2):119–124

45. Kianialaei A, Feyzabadi Z, Hamedi S, Qarayt M (2019) Althea officinalis in traditional medicine and modern phytotherapy. Issue S 9:8

46. Yi L et al (2004) Small molecules blocking the entry of severe acute respiratory syndrome coronavirus into host cells. J Virol 78(20):11334–11339. https://doi.org/10.1128/JVI.78.20.11334-11339.2004

47. Valanavidis A, Vlachogianni T (2013) Chapter 8 - Plant polyphenols: recent advances in epidemiological research and other studies on cancer prevention. in Studies in Natural Products Chemistry, vol. 39, Atta-ur-Rahman, Ed. Elsevier pp. 269–295. https://doi.org/10.1016/B978-0-44-62615-8.00008-4

48. Park J-Y et al (2017) Evaluation of polyphenols from Broussonetia papyrifera as coronavirus protease inhibitors. J Enzyme Inhib Med Chem 32(1):504–515. https://doi.org/10.1080/14756366.2016.1265519

49. Park J-Y et al (2016) Chalcones isolated from Angelica keiskei inhibit cysteine proteases of SARS-CoV. J Enzyme Inhib Med Chem 31(1):23–30. https://doi.org/10.1007/s10599-014-9832-1

50. Cho JK et al (2013) Geranylated flavonoids displaying SARS-CoV papain-like protease inhibition from the fruits of Paulownia tomentosa. Bioorg Med Chem 21(11):3051–3057. https://doi.org/10.1016/j.bmc.2013.03.027

51. Schwarz S et al (2014) Kaempferol derivatives as antiviral drugs against the 3a channel protein of coronavirus. Planta Med 80(2–3):177–182. https://doi.org/10.1055/s-0033-1360277

52. Zhang Y-Q, Luo J-G, Han C, Xu J-F, Kong L-Y (2015) Bioassay-guided preparative separation of angiotensin-converting enzyme inhibitory C-flavone glycosides from Desmodium strychorifolium by recycling complexation high-speed counter-current chromatography. J Pharm Biomed Anal 102:276–281. https://doi.org/10.1016/j.jpba.2014.09.027

53. Gandini A (1989) 19 - Polymers from renewable resources. in Comprehensive Polymer Science and Supplements, Allen G, Bevington JC Eds. Amsterdam: Pergamon pp. 527–573. https://doi.org/10.1016/B978-0-08-096701-0.00237-8

54. Kaczmarek B (2020) Tannic acid with antiviral and antibacterial activity as a promising component of biomaterials—a minireview. Mater Basel Switz 13(14):E3224. https://doi.org/10.3390/ma13143224
55. Chen C-N et al (2005) Inhibition of SARS-CoV 3C-like protease activity by theaflavin-3,3’-digallate (TF3). Evid-Based Complement Altern Med ECAM 2(2):209–215. https://doi.org/10.1093/ecom/nch081

56. Buckle J (2015) Chapter 3 - Basic plant taxonomy, basic essential oil chemistry, extraction, biosynthesis, and analysis. in Clinical Aromatherapy (Third Edition), Buckle J Ed. St. Louis: Churchill Livingstone pp. 37–72. https://doi.org/10.1093/ecam/neh081

57. Aldred EM, Buck C, Vall K (2009) Chapter 22 - terpenes. in Pharmacology, Aldred EM, Buck C, Vall K Eds. Edinburgh: Churchill Livingstone pp. 167–174. https://doi.org/10.1016/B978-0-443-06898-0.00022-0

58. Ryu YB et al (2010) SARS-CoV 3CLpro inhibitory effects of quinone-methide triterpenes from Tripterygium regelii. Bioorg Med Chem Lett 20(6):1873–1876. https://doi.org/10.1016/j.bmcl.2010.01.152

59. Wen C-C et al (2007) Specific plant terpenoids and lignoids possess potent antiviral activities against severe acute respiratory syndrome coronavirus. J Med Chem 50(17):4087–4095. https://doi.org/10.1021/jm070295s

60. Zhu D et al (2022) Efficient discovery of potential inhibitors for SARS-CoV-2 3C-like protease from herbal extracts using a native MS-based affinity-selection method. J Pharm Biomed Anal 209:114538. https://doi.org/10.1016/j.jpba.2021.114538

61. Marongiu B, Piras A, Porcedda S, Scorciapino A (2005) Chemical composition of the essential oil and supercritical CO2 extract of Commiphora myrrha (Nees) Engl. and of Acorus calamus L. J Agric Food Chem 53(20):7939–7943. https://doi.org/10.1021/jf051100x

62. Akbar S (2020) Handbook of 200 medicinal plants: a comprehensive review of their traditional medical uses and scientific justifications. Springer Nature

63. Mishra S, Pandey A, Manvati S (2020) Coumarin: an emerging antiviral agent. Helinyon 6(1):e03217. https://doi.org/10.1016/j.helinyon.2020.e03217

64. Ali MY, Seong SH, Jung HA, Choi JS (2019) Angiotensin-1-converting enzyme inhibitory activity of coumarins from Angelica decursiva. Mol Basel Swit 24(21):E3937. https://doi.org/10.1390/molecules24213937

65. Home - ClinicalTrials.gov. https://www.clinicaltrials.gov/. Accessed 13 Apr 2022

66. Supuran CT, Innocenti A, Mastrolorenzo A, Scozzafava A (2004) Antiviral sulfonamide derivatives. Mini Rev Med Chem 4(2):189–200. https://doi.org/10.2174/1389557043487402

67. Rey-Carrizo M et al (2014) Easily accessible polycyclic amines that inhibit the wild-type and amantadine-resistant mutants of the M2 channel of influenza A virus. J Med Chem 57(13):5738–5747. https://doi.org/10.1021/jm5005804

68. Urano E et al (2016) Alkyl amine bevirimat derivatives are potent and broadly active HIV-1 maturation inhibitors. Antimicrob Agents Chemother 60(1):190–197. https://doi.org/10.1128/AAC.02121-15

69. Kerru N, Gummidi L, Maddila S, Gangu KK, Jonnalagadda SB (2020) A review on recent advances in nitrogen-containing molecules and their biological applications. Mol Basel Switz 25(8):E1909. https://doi.org/10.1390/molecules25081909

70. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46(1–3):3–26. https://doi.org/10.1016/s0169-409x(00)00129-0

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.